Results 131 to 140 of about 4,931,245 (245)

Methylphenidate-Induced Acute Orofacial and Extremity Dyskinesia

open access: yes, 2013
Methylphenidate is a short-acting stimulant. In this article, the authors report a 7-year-old male patient who presented with orofacial and limb dyskinesia after his first dose of methylphenidate treatment for a diagnosis of attention-deficit ...
Yilmaz, Ayse Esra   +5 more
core   +1 more source

Suspected hyperthyroidism‐associated myoclonus in a cat

open access: yesVeterinary Record Case Reports, Volume 14, Issue 4, November 2026.
Abstract A 10‐year‐old, male, neutered domestic shorthair cat presented with a 2‐week history of progressively worsening myoclonic jerks predominantly involving the head. Jerks were continuous and marked at rest, but became less intense during activity.
Magdalena Maria Dyrka   +5 more
wiley   +1 more source

Explore the Mechanism of Xiaoyaosan for Treatment of Bipolar Disorder Based on Network Pharmacology, Experimental Validation and Molecular Docking

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 10, October 2026.
This study evaluates Xiaoyaosan (XYS) for bipolar disorder (BD) using network pharmacology and experimental validation. Molecular docking reveals interactions between active XYS compounds and potential core targets. Animal experiments confirm XYS alleviates BD‐like behaviors in mice by suppressing core targets, elucidating its multi‐target mechanism ...
Man Chen   +10 more
wiley   +1 more source

AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

open access: yes, 2000
OBJECTIVE: To evaluate the contribution of amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) glutamate receptors to the pathogenesis of parkinsonian signs and levodopa-induced dyskinesias. BACKGROUND: Motor fluctuations and dyskinesias reflect,
Blanchet, P. J.   +4 more
core  

Evaluation of the Peer Support Program (Student Drug Prevention) 1986-1987

open access: yes, 2019
The Peer Support program is a school based program funded by the National Campaign Against Drug Abuse (NCADA) as a drug prevention strategy. Prior to the existence of the NCADA the program was funded through the NSW Drug and Alcohol Authority.
Directorate of the Drug Offensive
core   +1 more source

Lung‐Cardiovascular Interactions and Derangements in ARDS

open access: yesComprehensive Physiology, Volume 16, Issue 5, October 2026.
This review proposes an anatomical near‐ and far‐field framework for lung‐cardiovascular interactions in ARDS. Grounded in pathological and biological studies, the evidence spans pulmonary vascular, right ventricular, and systemic endothelial derangements and reviews available evidence for targeted therapies.
Pablo A. Sanchez   +4 more
wiley   +1 more source

Fixed drug eruption induced by atenolol

open access: yes, 2009
H Belhadjali, O Trimech, M Youssef, I Elhani, J ZiliDepartment of Dermatology, Fattouma Bourguiba Hospital, Monastir, Tunisia Abstract: Fixed drug eruption (FDE) is characterized by recurrent well-defined lesions in the same location each time ...
H Belhadjali   +4 more
core  

Putative Mechanism of Action of Trazodone-Related Oromandibular Dyskinesia

open access: yesCase Reports in Psychiatry
This is a case report of three cases of trazodone-induced buccal–lingual dyskinesias. Each case demonstrated the distinct pattern of the development of this dyskinesia after trazodone exposure for several months.
Alan L. Schneider
doaj   +1 more source

3. Drug Induced Dyskinesia

open access: yesNihon Naika Gakkai Zasshi, 2007
Kondo, Tomoyoshi, Ishiguchi, Hiroshi
openaire   +2 more sources

Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

open access: yesNutrition in Clinical Practice, Volume 41, Issue 5, Page 1318-1333, October 2026.
Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation ...
Vikash Singhani   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy